BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 22

Jazz Pharmaceuticals PLC

JAZZNASDAQ
Trade with Public
Trade with Public
$241.46
0.720.3%
가까이에: Sep 21, 5:00 PM EST
$241.46
N/A
시간외: 4:02 PM EST
인수합병: Actio Biosciences, Inc was acquired by Jazz Pharmaceuticals (JAZZ) on Tuesday, September 15, 2026 for $820M
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 9 Quarters

Analyst Consensus — 19 Analysts

17Buy
2Hold
Consensus RatingBuy# Analysts19Avg. Consensus PT$258Upside to Avg. PT+6.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 11, 2026UBSAshwani VermaPT RaiseBuy$315→$337
Sep 10, 2026BarclaysEtzer DaroutPT RaiseOverweight$270→$271
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.
Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.
Benzinga Newsdesk

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Avi Kapoor

PRO
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $264 to $281.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved